Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.64 |
| ▸ | EYA2 | O00167 | 1/20 | 0.64 |
| ▸ | APP | P05067 | 1/20 | 0.64 |
| ▸ | ACE | P12821 | 1/20 | 0.64 |
| ▸ | BLM | P54132 | 2/20 | 0.61 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.61 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | DRD1 | P21728 | 1/20 | 0.61 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.61 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.61 |
| ▸ | DRD3 | P35462 | 1/20 | 0.61 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.61 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9159118 | 1.00 | TDP1 (0.64) | TDP1EYA2APPACEBLM | |
| SCHEMBL18811949 | 0.98 | TDP1 (0.65) | TDP1EYA2APPACEBLM | |
| Caldiamide SCHEMBL1114868 | 0.98 | TDP1 (0.65) | TDP1EYA2APPACEBLM | |
| SCHEMBL12153724 | 0.98 | TDP1 (0.65) | TDP1EYA2APPACEBLM | |
| Caldiamide SCHEMBL27165225 | 0.96 | TDP1 (0.62) | TDP1EYA2APPACEBLM | |
| Water SCHEMBL8533754 | 0.96 | TDP1 (0.62) | TDP1EYA2APPACEBLM | |
| SCHEMBL791881 | 0.92 | TDP1 (0.54) | TDP1EYA2APPACEBLM | |
| SCHEMBL9974572 | 0.91 | TDP1 (0.48) | TDP1EYA2APPACEBLM | |
| SCHEMBL13186220 | 0.91 | TDP1 (0.46) | TDP1EYA2APPACEBLM | |
| SCHEMBL5521537 | 0.90 | TDP1 (0.56) | TDP1EYA2APPACEBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230191368-A1 | Separation Matrix and Method of Separation | CYTIVA BIOPROCESS R&D AB (SE) | 2023-06-22 | — | — | US | disclosed |
| US-20230191368-A1 | Separation Matrix and Method of Separation | CYTIVA BIOPROCESS R&D AB (SE) | 2023-06-22 | — | — | US | disclosed |
| US-9675960-B2 | Immobilization of chelating groups for immobilized metal ion chromatography (IMAC) | MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2017-06-13 | — | — | US | disclosed |
| EP-2183049-B1 | USE OF IMMOBILIZED CHELATOR FOR PURIFICATION OF RECOMBINANT PROTEINS BY IMMOBILIZED METAL ION CHROMATOGRAPHY AND METHOD OF PURIFYING RECOMBINANT PROTEINS | MAX PLANCK GES ZUR FÖRDERUNG DER WISSENSCHAFTEN E V (DE) | 2014-09-17 | — | — | EP | disclosed |
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2012-03-22 | — | — | US | disclosed |
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2012-03-22 | — | — | US | disclosed |
| US-7977331-B1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2011-07-12 | — | — | US | disclosed |
| US-7977331-B1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2011-07-12 | — | — | US | disclosed |
| US-7659263-B2 | Thienopyrrole compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2010-02-09 | — | — | US | disclosed |
| US-7659263-B2 | Thienopyrrole compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2010-02-09 | — | — | US | disclosed |
| US-7439258-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM (CANADA) LTD (CA) | 2008-10-21 | — | — | US | disclosed |
| US-7439258-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM (CANADA) LTD (CA) | 2008-10-21 | — | — | US | disclosed |
| US-20070049593-A1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2007-03-01 | — | — | US | disclosed |
| US-20070049593-A1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049593-A1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | POLI, TERT, ZC3HAV1 | TDP1 3276/4885EYA2 4051/4885APP 4570/4885 |
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | POLI, TERT, ZC3HAV1 | TDP1 3276/4885EYA2 4051/4885APP 4570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.